Taro Pharmaceutical Industries (NYSE:TARO) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Taro Pharmaceutical Industries (NYSE:TARO) in a report published on Thursday. The brokerage issued a strong-buy rating on the stock.

Separately, HC Wainwright downgraded Taro Pharmaceutical Industries from a buy rating to a neutral rating and set a $43.00 target price on the stock. in a report on Thursday, January 18th.

Taro Pharmaceutical Industries Price Performance

Shares of NYSE:TARO opened at $42.13 on Thursday. The company has a market capitalization of $1.58 billion, a P/E ratio of 34.53 and a beta of 0.61. Taro Pharmaceutical Industries has a 1 year low of $23.92 and a 1 year high of $45.76. The business’s 50 day simple moving average is $42.17 and its 200 day simple moving average is $39.63.

Taro Pharmaceutical Industries (NYSE:TARO) last issued its quarterly earnings results on Thursday, January 25th. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.30 by $0.26. The business had revenue of $157.15 million for the quarter, compared to the consensus estimate of $154.90 million. Taro Pharmaceutical Industries had a return on equity of 3.26% and a net margin of 7.48%. On average, sell-side analysts anticipate that Taro Pharmaceutical Industries will post 1.38 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TARO. Ameritas Investment Partners Inc. bought a new position in Taro Pharmaceutical Industries during the 2nd quarter worth $26,000. UBS Group AG raised its position in Taro Pharmaceutical Industries by 71.6% during the 2nd quarter. UBS Group AG now owns 925 shares of the company’s stock worth $34,000 after purchasing an additional 386 shares during the last quarter. Bank of America Corp DE raised its position in shares of Taro Pharmaceutical Industries by 126.5% in the 1st quarter. Bank of America Corp DE now owns 1,506 shares of the company’s stock worth $37,000 after acquiring an additional 841 shares in the last quarter. Royal Bank of Canada raised its position in shares of Taro Pharmaceutical Industries by 664.0% in the 2nd quarter. Royal Bank of Canada now owns 1,039 shares of the company’s stock worth $39,000 after acquiring an additional 903 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of Taro Pharmaceutical Industries by 5,988.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,035 shares of the company’s stock worth $39,000 after acquiring an additional 1,018 shares in the last quarter. 91.40% of the stock is owned by institutional investors.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.